RYR2 and cancer: The results showed that the mutational status of RYR2 did not stratify the survival in all cancer types (Fig. 8A), while significant stratification can be found in bladder urothelial carcinoma (BLCA) (P = 0.00071, Fig. 8B), LUSC (P = 0.036, Fig. 8D) and uterine carcinosarcoma (UCS) (P = 0.034, Fig. 8F).